-

05:46:23 PM

ZYNE Stock News

ZYNE - Zynerba Pharmaceuticals Inc

06/21/22 8:05 PM

Nasdaq : ZYNE

clinical trial

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

– The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments – – Safety data reinforce excellent tolerability profile of Zygel – – Company will focus resources on FXS and 22q development – – Cash runway extended through

RHEA-AI

neutral

06/01/22 7:00 AM

Nasdaq : ZYNE

Zynerba Pharmaceuticals Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

RHEA-AI

very positive

05/24/22 7:00 AM

Nasdaq : ZYNE

Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation and a poster presentation

RHEA-AI

neutral

05/17/22 7:00 AM

Nasdaq : ZYNE

conferences

Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive

RHEA-AI

neutral

05/16/22 7:00 AM

Nasdaq : ZYNE

earnings

Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

– Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 – – Topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) expected mid-year 2022 – – $69.7

RHEA-AI

very positive

05/11/22 1:30 PM

Nasdaq : ZYNE

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced

RHEA-AI

positive

05/09/22 4:57 PM

Nasdaq : ZYNE

Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation at the International

RHEA-AI

neutral

05/02/22 7:00 AM

Nasdaq : ZYNE

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster at the 2022 Society of Biological Psychiatry (SOBP)

RHEA-AI

neutral

04/21/22 7:00 AM

Nasdaq : ZYNE

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2022 Society of

RHEA-AI

neutral

04/05/22 7:00 AM

Nasdaq : ZYNE

conferences

Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

ZYNE Data

Websitewww.zynerba.com
CeoArmando Anido
Security nameZynerba Pharmaceuticals Inc
Issue typecs
Sic code2834
Employees26
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address80 W. Lancaster Avenue
Address2Suite 300
StatePennsylvania
CityDevon
Zip19333
CountryUS
Phone14845817505

About Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies.